AIM ImmunoTech Inc. (AIM) stock
AIMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.15+0.00 (+0.13%)
Close on Nov 12, 2026Market cap $4.52MP/E –Yield –
AIM ImmunoTech total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
AIM ImmunoTech's total debt was $1.44M at Sep 30, 2026. For fiscal 2025 it was $4.48M, up 94.0% from the year before. The highest annual figure on record is $4.48M in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.48M | +94.0% |
| FY2024 | Dec 31, 2024 | $2.31M | +9.5% |
| FY2020 | Dec 31, 2020 | $2.11M | -9.1% |
| FY2019 | Dec 31, 2019 | $2.32M | -7.9% |
| FY2018 | Dec 31, 2018 | $2.52M | +37.2% |
| FY2017 | Dec 31, 2017 | $1.84M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.44M | -23.6% |
| Q2 FY2026 | Jun 30, 2026 | $3.62M | +58.1% |
| Q1 FY2026 | Mar 31, 2026 | $4.21M | +116.1% |
| Q4 FY2025 | Dec 31, 2025 | $4.48M | +94.0% |
| Q3 FY2025 | Sep 30, 2025 | $1.88M | -31.2% |
| Q2 FY2025 | Jun 30, 2025 | $2.29M | -13.2% |
| Q1 FY2025 | Mar 31, 2025 | $1.95M | -24.2% |
| Q4 FY2024 | Dec 31, 2024 | $2.31M | +12.5% |
| Q3 FY2024 | Sep 30, 2024 | $2.73M | +29.7% |
| Q2 FY2024 | Jun 30, 2024 | $2.64M | +22.1% |
| Q1 FY2024 | Mar 31, 2024 | $2.57M | +16.2% |
| Q1 FY2021 | Mar 31, 2021 | $2.05M | -9.6% |
| Q4 FY2020 | Dec 31, 2020 | $2.11M | -9.1% |
| Q3 FY2020 | Sep 30, 2020 | $2.16M | -49.2% |
| Q2 FY2020 | Jun 30, 2020 | $2.21M | -8.4% |
| Q1 FY2020 | Mar 31, 2020 | $2.27M | -8.1% |
| Q4 FY2019 | Dec 31, 2019 | $2.32M | -7.9% |
| Q3 FY2019 | Sep 30, 2019 | $4.25M | +65.7% |
| Q2 FY2019 | Jun 30, 2019 | $2.42M | -7.4% |
| Q1 FY2019 | Mar 31, 2019 | $2.47M | -7.3% |
| Q4 FY2018 | Dec 31, 2018 | $2.52M | +37.2% |
| Q3 FY2018 | Sep 30, 2018 | $2.57M | +75.0% |
| Q2 FY2018 | Jun 30, 2018 | $2.61M | +405.2% |
| Q1 FY2018 | Mar 31, 2018 | $2.66M | – |
| Q4 FY2017 | Dec 31, 2017 | $1.84M | – |
| Q3 FY2017 | Sep 30, 2017 | $1.47M | – |
| Q2 FY2017 | Jun 30, 2017 | $517.00K | – |
See a number that looks wrong?